Pfizer surprised Wall Street with a prediction for a bigger-than-expected sales drop this year for two key products: its COVID-19 vaccine and treatment.
The drugmaker also released an earnings forecast that is below analyst expectations, sending shares lower before the opening bell Tuesday.
Pfizer expects sales of both the vaccine Comirnaty and the treatment Paxlovid to tumble next year before starting to rebound.
That drop was expected as the drugmaker shifts from supplying government contracts to sales on the commercial market in the United States.
But Pfizer said Tuesday that it expects Comirnaty sales to tumble 64% to about $13.5 billion this year.
It predicts a 58% drop for Paxlovid to about $8 billion.
Wall Street expects more than $14 billion in sales from Comirnaty and another $10.5 billion from Paxlovid, according to FactSet.
Overall, Pfizer predicts that adjusted earnings will range between $3.25 and $3.45 per share in the new year.
Analysts forecast earnings of $4.34 per share.
In the recently completed fourth quarter, Pfizer booked nearly half of its $24.29 billion in revenue from its top-selling COVID-19 vaccine Comirnaty.
The company brought in another $1.8 billion from Paxlovid.
The drugmaker posted adjusted earnings of $1.14 per share.
Analysts forecast fourth-quarter earnings of $1.05 per share on $24.38 billion in revenue, according to FactSet.
Shares of New York-based Pfizer Inc. slid nearly 3%, or $1.25, to $42.30 before markets opened Tuesday.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve hit your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Quarterly Starter
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Access to Exclusive Premium Stories Online
Over 30 behind the paywall stories daily, handpicked by our editors for subscribers


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app